Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Accured Expenses (2022 - 2026)

Axsome Therapeutics' Change in Accured Expenses history spans 5 years, with the latest figure at $17.2 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 2006.23% to $17.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $100.2 million, a 53.38% increase, with the full-year FY2025 number at $83.7 million, up 49.37% from a year prior.
  • Change in Accured Expenses hit $17.2 million in Q1 2026 for Axsome Therapeutics, up from $7.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for AXSM hit a ceiling of $54.2 million in Q3 2025 and a floor of -$8.4 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $14.0 million across 5 years, with a median of $11.4 million in 2023.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 217.81% in 2024 and later skyrocketed 2006.23% in 2026.
  • Tracing AXSM's Change in Accured Expenses over 5 years: stood at $13.2 million in 2022, then fell by 13.91% to $11.4 million in 2023, then surged by 125.95% to $25.7 million in 2024, then tumbled by 72.05% to $7.2 million in 2025, then surged by 140.16% to $17.2 million in 2026.
  • Business Quant data shows Change in Accured Expenses for AXSM at $17.2 million in Q1 2026, $7.2 million in Q4 2025, and $54.2 million in Q3 2025.